Compositions of optically pure (-) norcisapride and another ther

Details Compositions of optically pure (-) norcisapride and another ther Compositions of optically pure (-) norcisapride and another ther

1998-10-13

2000-12-05

Jarvis, William R. A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 31445

Patent

active

061567701

ABSTRACT:
Pharmaceutical compositions are disclosed utilizing the optically pure (-) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dyspepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (-) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.

REFERENCES:
patent: 4962115 (1990-10-01), Van Daele
patent: 5057525 (1991-10-01), Van Daele
patent: 5137896 (1992-08-01), Van Daele
patent: 5712293 (1998-01-01), McCullough et al.
patent: 5739151 (1998-04-01), McCullough et al.
Barnes, N.M., et al, "Identification of 5-HT.sub.3 Recognition Sites in the Ferret Area Postrema," J. Pharm. Pharmacol., 40:586-588 (1988).
Barone, et al., "Bioavailability of Three Oral Dosage Forms of Cisapride, a Gastrointestinal Stimulant Agent," Clinical Pharmacy, 6:640-645 (1987).
Clarke, D.E., et al., "The 5-HT.sub.3 Receptor: Naughty, but Nice," Trends in Pharmacological Sciences, 10:385-386 (1989).
Costall, B. et al., "Emesis Induced by Cisplatin in the Ferret as a Model for the Detection of Anti-Emetic Drugs," Neuropharmacology, 26:1321-1326 (1987).
Craig & Clark, "5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig Lleum," Brit. J. Pharmacol., 96:247 (1989).
Decktor, D.L., et al., "Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364, 718, on Gastric Emptying in the Rat," Eur. J. Pharmacol., 147:313-316 (1988).
Dumuis, A., et al., "The Gastrointestinal Prokinetic Benzamide Derivatives are Agontist at the Non-Classical 5-HT Receptor (5-HT.sub.4) Positively Coupled to Adenylate Cyclase in Neurons," N.S. Arch. Pharmacol., 340:403-410 (1989).
Fernandez & Massingham, "Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Meoclopramide-like Drugs," Life Sci., 36:1-14 (1985).
Frazer, A., et al., "Subtypes of Receptors for Serotonin," Annual Rev. of Pharmacology and Toxicology, 30:307-348 (1990).
Gladziwa, U., et al., "Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis," Clinical Pharmacology, 50:6:673-681 (1991).
Gullikson, G.W., et al., "Relationship of Serotonin-3 Receptor Antagonist Activity to Gastric Emptying and Motor-Stimulating Actions of Prokinetic Drugs in Dogs," J. Pharmacol. Experimen. Therp., 258(1):103-110 (1991).
Jamali, F., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls," Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Krejs, G.J., "Serotonine intestinale, une cible therapeutique," Med. Chir. Dig., 22:7:415-416 (1993).
Lauwers, W., et al., "Identification of a Biliary Metabolite of Cisapride," Biomedical and Environmental Mass Spectrometry, 15:323-328 (1988).
Lavrijsen, K., et al., "The Role of CYP3A4 in the In-Vitro Metabolism of Cisapride in Human Liver Microsomes and In-Vitro and In-Vivo Interactions of Cisapride with Co-Administered Drugs," Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation (1995).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Dogs and Humans After Oral Administration," Drug Metabolism and Disposition, 16:3:403-419 (1988).
Milo, R., "Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive Of A Motility Disorder: A Two-Step Pilot Evaluation of Cisapride," Curr. Therapeutic Research, 36:5:1053-1062 (1984).
Nemeth, P.R., "Gastrointestinal motility stimulating drugs and 5-HT receptors or Myenteric Neurons," Eur. J. Pharmacol., 166:387-391 (1989).
Porsius, A.J., et al., "Farmacotoets 6A," Farmacotherapie, 129:9:214-217 (1994).
Reyntjens, A., et al., "Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties," Current Therapeutic Research, 36:5:1045-1052 (1984).
Schapira, M., et al., "The Current Status of Gastric Prokinetic Drugs," Acta Gastroenterolog. Belg., LIII:446-457 (1990).
Schiavi, G.B. et al., "Identification of Serotonin 5-HT.sub.4 Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding," Neuropharmacology, 33:543-549 (1994).
Schuurkes, J.A.J., et al., "Motor-Stimulating Properties of Cisapride on Isolated Gastrointestinal Preparations of the Guinea Pig." J. Pharmacol. Exp. Ther., 234:775-783 (1985).
Stacher, G., et al., "Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man," Digestive Diseases and Sciences, 32:11:1223-1230 (1987).
Van Peer, A., et al., "Clinical Pharmacokinetics of Cisapride," Progress in the Treatment of Gastrointestinal Motility Disorders: The Role of Cisapride, Proceedings of a Symposium in Frankfurt Excerpta Medica, pp. 23-29 (1988).
Williams & Burks, "Cisapride Increases Gastric Emptying Without Affecting Small or Large Bowel Transit," Proc. West. Pharmacol. Soc., 28:47-50 (1985).
Zuccato, E., et al., "The Effects of S(-) and R(+) Sulpiride, Metoclopramide, Cisapride and Domperidone on the Small Intestine Suggest DA.sub.2 -Receptors are Involved in the Control of Small Intestinal Transit Time in Rats," Pharmacological Research, 26:2:179-185 (1992).
Thomas F. Burks, Principles of Pharmacology, 1996, pp. 1093-1100.

Affiliated with

Also associated with

Rating

Compositions of optically pure (-) norcisapride and another ther does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of optically pure (-) norcisapride and another ther, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of optically pure (-) norcisapride and another ther will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-962093